Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Wierda

Showing results (161-170 of 181) with videos related to

Pageof 19
Sort By:
British Journal of Haematology|October 23, 2015
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemiaFarhad Ravandi, Jeffrey L Jorgensen, Susan M O'Brien, et al.
Blood Advances|October 26, 2022
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLLNitin Jain, Jayastu Senapati, Beenu Thakral, et al.
British Journal of Haematology|September 12, 2015
CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphomaKoichi Takahashi, Mariela Sivina, Julia Hoellenriegel, et al.
Leukemia & Lymphoma|October 20, 2021
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapyJorge M Ramos Perez, Keyur P Patel, Sanam Loghavi, et al.
Blood|March 14, 2019
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemiaIan W Flinn, John G Gribben, Martin J S Dyer, et al.
The New England Journal of Medicine|February 6, 2020
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid TumorsEnli Liu, David Marin, Pinaki Banerjee, et al.
Leukemia & Lymphoma|March 8, 2022
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemiaSarah Tettamanti, Maria Caterina Rotiroti, Greta Maria Paola Giordano Attianese, et al.
Blood|April 16, 2010
microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survivalSimona Rossi, Masayoshi Shimizu, Elisa Barbarotto, et al.
Blood|December 23, 2016
Long-term outcome of acute promyelocytic leukemia treated with all-<i>trans</i>-retinoic acid, arsenic trioxide, and gemtuzumabYasmin Abaza, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Blood Advances|March 8, 2023
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensityAlexandre Bazinet, Tapan Kadia, Nicholas J Short, et al.
Pageof 19

Showing results (161-170 of 181) with videos related to

Sort By:
Pageof 19
British Journal of Haematology|October 23, 2015
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemiaFarhad Ravandi, Jeffrey L Jorgensen, Susan M O'Brien, et al.
Blood Advances|October 26, 2022
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLLNitin Jain, Jayastu Senapati, Beenu Thakral, et al.
British Journal of Haematology|September 12, 2015
CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphomaKoichi Takahashi, Mariela Sivina, Julia Hoellenriegel, et al.
Leukemia & Lymphoma|October 20, 2021
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapyJorge M Ramos Perez, Keyur P Patel, Sanam Loghavi, et al.
Blood|March 14, 2019
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemiaIan W Flinn, John G Gribben, Martin J S Dyer, et al.
The New England Journal of Medicine|February 6, 2020
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid TumorsEnli Liu, David Marin, Pinaki Banerjee, et al.
Leukemia & Lymphoma|March 8, 2022
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemiaSarah Tettamanti, Maria Caterina Rotiroti, Greta Maria Paola Giordano Attianese, et al.
Blood|April 16, 2010
microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survivalSimona Rossi, Masayoshi Shimizu, Elisa Barbarotto, et al.
Blood|December 23, 2016
Long-term outcome of acute promyelocytic leukemia treated with all-<i>trans</i>-retinoic acid, arsenic trioxide, and gemtuzumabYasmin Abaza, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Blood Advances|March 8, 2023
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensityAlexandre Bazinet, Tapan Kadia, Nicholas J Short, et al.
Pageof 19